-- フィッチ・レーティングスは最近の発表で、米イラン戦争の長期化が間近に迫った作付けシーズンを前に肥料供給をさらに逼迫させ、食料価格の上昇圧力がアジアの新興国市場に重くのしかかる可能性があると指摘した。 フィッチによると、肥料の供給不足と価格上昇圧力は生産コストの上昇、施肥量の抑制、そして作物の収穫量減少につながり、今年の利益率と食料価格に影響を与えるという。 フィッチは、湾岸地域は世界の肥料供給の大部分を担っており、特に天然ガスが主要な原料として重要な役割を果たしていると指摘した。 また、同格付け機関は、中国などのアジアの主要輸出国が少なくとも年央までは肥料の出荷をさらに制限すると予想している。 フィッチによると、窒素系尿素の価格は戦前の1トン当たり約465ドルから約700ドルへと50%上昇した。 格付け機関フィッチは、肥料使用量や作付け面積の減少は、年末にかけての作物収量の低下と食料価格の高騰リスクを悪化させる可能性があると指摘した。 同地域の新興国は国内生産への依存度が高いため、肥料供給量の減少は作付け面積や収量の制約下において深刻な影響を及ぼすとフィッチは述べた。 モルディブ、モンゴル、フィリピン、バングラデシュ、スリランカなど、輸入食料への依存度が高い国々では、国内収穫量の減少に加え、世界的な食料価格の高騰や輸出制限が重なることで、より深刻な状況が生じるとフィッチは指摘した。 フィッチは、世界食糧計画(WFP)の発表を引用し、2026年半ば以降も紛争が続き、原油価格が高騰した場合、アジアでは新たに910万人が深刻な食料不安に陥る可能性があり、これは戦前と比べて24%の増加になると指摘した。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.